Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Glenmark Collaborates With Others For HIV-Related Drug

This article was originally published in PharmAsia News

Executive Summary

Glenmark Pharmaceuticals announced collaboration with other Indian drug makers to develop an HIV drug with several applications beyond the disease itself. The firm expects by 2010 to be able to file for U.S. approval of its crofelemer for treating several ailments, including diarrhea associated with HIV. The ability to file for the drug resulted from collaboration between Napo Pharmaceuticals and Salex Pharmaceuticals. Glenmark expects the drug to be worth $80 million in the HIV market. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts